ESPERION Announces Plan for Transformative Long-Term Growth

Go back to ESPERION Announces Plan for Transformative Long-Term Growth

Credit Suisse Downgrades Esperion Therapeutics (ESPR) to Neutral

October 18, 2021 6:08 PM UTC

Credit Suisse analyst Judah Frommer downgraded Esperion Therapeutics (NASDAQ: ESPR) from to Neutral with a price target of $11.00 (from $28.00).

The analyst comments "Following a challenged launch for bempedoic acid during the Covid-19 pandemic, along with administrative complications borne out of preauthorization requirements for many prescriptions, Esperion communicated a shift in strategy to... More